CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,061 enrolled
Drug / intervention
Experimental: Tezepelumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03347279
NCT03347279Phase 3Completed
CompareCT.gov

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)

AstraZeneca·interventional·Posted Nov 20, 2017·Updated Nov 26, 2021

In Brief

A Phase 3 clinical trial evaluating Experimental: Tezepelumab and Placebo for Asthma. Completed, enrolled 1,061 participants across 289 sites in 18 countries.

Detailed Summary

A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Australia, Austria, Brazil, Canada, France, Germany, Israel, Japan, Russia, Saudi Arabia, South Africa, South Korea, Taiwan, Ukraine, United Kingdom, United States, Vietnam
CollaboratorsAmgen

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedNov 20, 2017
Enrollment StartNov 23, 2017
Primary CompletionSep 8, 2020
Study CompletionNov 12, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.6 years ago

Interventions

Experimental: Tezepelumabbiological

Tezepelumab subcutaneous injection

Placeboother

Placebo subcutaneous injection